NYXH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nyxoah SA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading weakly in pre-market at 2.83, down 3.08%, and the technical setup does not show a clear bullish entry. While analysts still see upside potential, recent target cuts and a downgrade to Hold show mixed Wall Street confidence. With no positive news catalyst, no insider or hedge fund buying trend, and no strong Intellectia signal, the better call is to wait rather than buy immediately.
The current trend is neutral to mildly bearish. MACD histogram is slightly positive at 0.0125 but is contracting, which suggests momentum is fading. RSI_6 at 34.236 is near oversold but still not a strong reversal signal. Moving averages are converging, pointing to a lack of trend conviction. Price is also sitting below the pivot level of 3.104 and near support at 2.921, with pre-market weakness increasing the chance of further downside before a stronger base forms.
Piper Sandler raised the price target to $7 and kept an Overweight rating, citing 25% quarter-over-quarter U.S. net-revenue growth and progress in the Genio launch. Analysts still see long-term high-growth potential if commercialization continues to improve.
Stifel downgraded the stock to Hold and cut its target to $5, citing ongoing reimbursement challenges in the HGNS market. Earlier target cuts from Stifel and Baird also show waning near-term confidence. There has been no news in the recent week, and hedge fund and insider trading trends are both neutral. Similar-pattern trend data also points to weak near-term returns over the next day, week, and month.
Latest quarter financials were not fully provided, but the analyst commentary indicates the most recent quarter showed 25% quarter-over-quarter U.S. net-revenue growth, which is a constructive sign for the latest reported quarter. That said, the company still appears to be early in its U.S. rollout and may need additional balance-sheet support, so growth is improving but not yet strong enough to justify an aggressive long-term buy today.
Analyst sentiment is mixed to cautious. Piper Sandler is bullish with an Overweight rating and a $7 target, but it lowered its target from $9. Stifel turned more cautious, downgrading Nyxoah to Hold from Buy and cutting its target to $5 from $8. Baird remains Neutral with a much lower $4.62 target. Overall, Wall Street sees some upside, but the pros-versus-cons view is split, with growth potential offset by reimbursement and financing concerns.
